Komori
Other Disclosures4598Delta-Fly Pharma,Inc.Pharmaceuticals

Notice Regarding the Start of Patient Enrollment in the Investigator-Initiated Clinical Trial of DFP-11207 for Biliary Tract Cancer

Enrollment of the first patient has begun in the investigator-initiated Phase 1/2 clinical trial of DFP-11207 for biliary tract cancer. The trial is being conducted at 3 sites.

Worth reading
68In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Improvement
Direction inferred from the company’s description.
Scale
1
Enrollment of the first subject
Wording
Definitive
How definitive the wording is.

Announced details

DFP-11207 (oral formulation)
Applicable field (uses covered by this announcement)

Biliary tract cancer

Launch dateJanuary 2026 (trial start; actual)
What the company reported numerically
Usage history

Enrollment of the first subject commenced (not specified whether this is cumulative or as of a point in time)

Relationship between the counterparty and the company
Delta-Fly Pharma,Inc.4598
Relationship with the Company

Relationship based on an agreement relating to the investigator-initiated clinical trial.

CounterpartyGeneral Incorporated Association Japan Hepato-Biliary-Pancreatic Oncology Network (JON-HBP)

Chuo-ku, Tokyo. Its Representative Director and Chairperson is Furuse Junji (古瀬純司). This general incorporated association provides support for clinical research and information on malignant tumors of the liver, biliary tract and pancreas.

Registration number and expiry date

jRCT2031250656 (listing number in the Clinical Research Submission and Disclosure System)

Location (as indicated in this announcement)

Local Independent Administrative Agency Kanagawa Prefectural Hospital Organization, Kanagawa Cancer Center, Specific Function Hospital / Local Independent Administrative Agency Osaka Prefectural Hospital Organization, Osaka International Cancer Institute, Local Independent Administrative Agency Saitama Prefectural Hospital Organization, Saitama Cancer Center

3 sites

In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.

Source (materials cited by the company)

National Cancer Center Cancer Information Service; Clinical Research Submission and Disclosure System (jRCT)

Announced details
ItemDetails
Names of Products / Services CoveredDFP-11207 (oral formulation)
CounterpartyGeneral Incorporated Association Japan Hepato-Biliary-Pancreatic Oncology Network (JON-HBP)
Counterparty overviewChuo-ku, Tokyo. Its Representative Director and Chairperson is Furuse Junji (古瀬純司). This general incorporated association provides support for clinical research and information on malignant tumors of the liver, biliary tract and pancreas.
Relationship with the CompanyRelationship based on an agreement relating to the investigator-initiated clinical trial.
Launch dateJanuary 2026 (trial start; actual)
Applicable areaBiliary tract cancer
Registration number and expiry datejRCT2031250656 (listing number in the Clinical Research Submission and Disclosure System)
LocationLocal Independent Administrative Agency Kanagawa Prefectural Hospital Organization, Kanagawa Cancer Center, Specific Function Hospital / Local Independent Administrative Agency Osaka Prefectural Hospital Organization, Osaka International Cancer Institute, Local Independent Administrative Agency Saitama Prefectural Hospital Organization, Saitama Cancer Center
Location scale3 sites
Usage historyEnrollment of the first subject commenced (not specified whether this is cumulative or as of a point in time)
SourceNational Cancer Center Cancer Information Service; Clinical Research Submission and Disclosure System (jRCT)
Items this document does not state (7)
Contract ValueOffering priceContract DateAward/certification nameAwarding / certifying bodyQuantitative EffectsImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Because JON-HBP reported that enrollment of the first subject had begun.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding the Start of Patient Enrollment in the Investigator-Initiated Clinical Trial of DFP-11207 for Biliary Tract Cancer | Delta-Fly Pharma,Inc. (4598) timely disclosure | Komori